同大類(lèi)學(xué)科其它級(jí)別期刊：
中科院 1區(qū) 期刊 JCR Q1 期刊 中科院 2區(qū) 期刊 JCR Q2 期刊 中科院 3區(qū) 期刊 JCR Q3 期刊 中科院 4區(qū) 期刊 JCR Q4 期刊Journal Of Medicinal Chemistry SCIE
國(guó)際簡(jiǎn)稱(chēng)：J. Med. Chem. 參考譯名：藥物化學(xué)雜志
主要研究方向：醫(yī)學(xué)-醫(yī)藥化學(xué) 非預(yù)警期刊 審稿周期： 約2.1個(gè)月
《藥物化學(xué)雜志》(Journal Of Medicinal Chemistry)是一本由American Chemical Society出版的以醫(yī)學(xué)-醫(yī)藥化學(xué)為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開(kāi)放期刊，近三年沒(méi)有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。
- 1區(qū) 中科院分區(qū)
- Q1 JCR分區(qū)
- 922 年發(fā)文量
- 6.8 IF影響因子
- 開(kāi)放 是否OA
- 240 H-index
- 1959 創(chuàng)刊年份
- Biweekly 出版周期
- English 出版語(yǔ)言
The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.
Some specific areas that are appropriate include the following:
* Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.
* Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication.
*Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.
* Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.
*Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge.
* Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules.
* Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.
* Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.
Journal Of Medicinal Chemistry期刊信息
- ISSN：0022-2623
- 出版語(yǔ)言：English
- 是否OA：開(kāi)放
- E-ISSN：1520-4804
- 出版地區(qū)：UNITED STATES
- 是否預(yù)警：否
- 出版商：American Chemical Society
- 出版周期：Biweekly
- 創(chuàng)刊時(shí)間：1959
- 開(kāi)源占比：0.099
- Gold OA文章占比：13.77%
- OA被引用占比：0.0691...
- 出版國(guó)人文章占比：0.14
- 出版撤稿占比：0.0011...
- 研究類(lèi)文章占比：98.81%
Journal Of Medicinal Chemistry CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）
| CiteScore | SJR | SNIP | CiteScore 指數(shù) | ||||||||||||
| 12.8 | 1.986 | 1.594 |
|
名詞解釋?zhuān)?/b>CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量 注：文獻(xiàn)類(lèi)型包括：文章、評(píng)論、會(huì)議論文、書(shū)籍章節(jié)和數(shù)據(jù)論文。
Journal Of Medicinal Chemistry中科院評(píng)價(jià)數(shù)據(jù)
中科院 2023年12月升級(jí)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 1區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
中科院 2022年12月升級(jí)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 1區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
中科院 2021年12月舊的升級(jí)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 1區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
中科院 2021年12月基礎(chǔ)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 2區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
中科院 2021年12月升級(jí)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 1區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
中科院 2020年12月舊的升級(jí)版
| Top期刊 | 綜述期刊 | 大類(lèi)學(xué)科 | 小類(lèi)學(xué)科 | ||
| 是 | 否 | 醫(yī)學(xué) | 1區(qū) | CHEMISTRY, MEDICINAL 藥物化學(xué) | 1區(qū) |
Journal Of Medicinal Chemistry JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）
| 按JIF指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
| 學(xué)科：CHEMISTRY, MEDICINAL | SCIE | Q1 | 4 / 72 |
95.1% |
| 按JCI指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
| 學(xué)科：CHEMISTRY, MEDICINAL | SCIE | Q1 | 1 / 72 |
99.31% |
Journal Of Medicinal Chemistry歷年數(shù)據(jù)統(tǒng)計(jì)
影響因子
中科院分區(qū)
Journal Of Medicinal Chemistry中國(guó)學(xué)者發(fā)文選摘
-
1、Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small- cell Lung Cancer
Author: Pei, Junping; Wang, Guan; Wang, Aoxue; Wu, Chengyong; Pan, Xiaoli; Shuai, Wen; Bu, Faqian; Zhu, Yumeng; Wang, Yuxi; Ouyang, Liang; Li, Weimin
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00027
-
2、Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Author: Zhu, Chenyu; Ze, Shuyin; Zhou, Ronghui; Yang, Xinyu; Wang, Haojie; Chai, Xiaolei; Fang, Meimiao; Liu, Mingyao; Wang, Yonghui; Lu, Weiqiang; Xie, Qiong
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4734-4754. DOI: 10.1021/acs.jmedchem.2c018604734J
-
3、Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway
Author: Zhang, Xinqi; Han, Qianyu; Hou, Ruilin; Xu, Lijuan; Zhang, Wannian; Xing, Chengguo; Xue, Lei; Zhuang, Chunlin
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 5261-5278. DOI: 10.1021/acs.jmedchem.3c00197
-
4、Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives
Author: Xie, Yuting; Yue, Lin; Shi, Yaojie; Su, Xingping; Gan, Cailing; Liu, Hongyao; Xue, Taixiong; Ye, Tinghong
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4342-4360. DOI: 10.1021/acs.jmedchem.2c01753
-
5、Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Author: Luo, Guangmei; Wang, Bingrui; Hou, Qiangqiang; Wu, Xiaoxing
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4324-4341. DOI: 10.1021/acs.jmedchem.2c01729
-
6、Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation
Author: Li, Shao-Xian; Wang, Si-Wei; Chen, Lin-Hai; Zhang, Qing; Lu, Dan; Chen, Jing; Fang, You-Chen; Gu, Min; Xie, Xin; Nan, Fa-Jun
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 8, pp. 5820-5838. DOI: 10.1021/acs.jmedchem.3c00053
-
7、Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1
Author: Gallego, Rebecca A.; Bernier, Louise; Chen, Hui; Cho-Schultz, Sujin; Chung, Loanne; Collins, Michael; Del Bel, Matthew; Elleraas, Jeff; Jones, Cinthia Costa; Cronin, Ciaran N.; Edwards, Martin; Fang, Xu; Fisher, Timothy; He, Mingying; Hoffman, Jacqui; Huo, Ruiduan; Jalaie, Mehran; Johnson, Eric; Johnson, Ted W.; Kania, Robert S.; Kraus, Manfred; Lafontaine, Jennifer; Le, Phuong; Liu, Tongnan; Maestre, Michael; Matthews, Jean; McTigue, Michele; Miller, Nichol; Mu, Qiming; Qin, Xulong; Ren, Shijian; Richardson, Paul; Rohner, Allison; Sach, Neal; Shao, Li; Smith, Graham; Su, Ruirui; Sun, Bin; Timofeevski, Sergei; Tran, Phuong; Wang, Shuiwang; Wang, Wei; Zhou, Ru; Zhu, Jinjiang; Nair, Sajiv K.
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4888-4909. DOI: 10.1021/acs.jmedchem.2c02038
-
8、Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers
Author: Qiu, Qianqian; Chi, Fanglian; Zhou, Daoguang; Xie, Zhancheng; Liu, Yunxiao; Wu, Hanyu; Yin, Ziyu; Shi, Wei; Qian, Hai
Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00036
Journal Of Medicinal Chemistry同類(lèi)期刊
-
生物醫(yī)學(xué)與藥物治療
Biomedicine & Pharmacotherapy
中科院 2區(qū) JCR Q1
-
藥理學(xué)前沿
Frontiers In Pharmacology
中科院 2區(qū) JCR Q1
-
公共衛(wèi)生前沿
Frontiers In Public Health
中科院 3區(qū) JCR Q2
-
Bmc精神病學(xué)
Bmc Psychiatry
中科院 2區(qū) JCR Q2
-
Bmc神經(jīng)病學(xué)
Bmc Neurology
中科院 3區(qū) JCR Q3
-
Bmc公共衛(wèi)生
Bmc Public Health
中科院 2區(qū) JCR Q1
-
Bmc 女性健康
Bmc Womens Health
中科院 3區(qū) JCR Q2
-
美康
Medcomm
中科院 3區(qū) JCR Q1
免責(zé)聲明
若用戶(hù)需要出版服務(wù)，請(qǐng)聯(lián)系出版商：AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, USA, DC, 20036。